|
مقاله
|
Abstract
|
|
|
Title:
|
Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial
|
Author(s):
|
Heshmatollah Ghanbari, Farzan Kianersi, Seyed Ali Sonbolestan, Mohammad-Ali Abtahi, Mojataba Akbari, Zahra-Alsadat Abtahi, Seyed-Hossein Abtahi, Hamidreza Jahanbani-Ardakani
|
Presentation Type:
|
Oral
|
Subject:
|
Posterior Segment and Uveitis
|
Others:
|
|
Presenting Author:
|
|
Name:
|
Seyed Ali Sonbolestan
|
Affiliation :(optional)
|
Isfahan Eye Research Center (IERC), Feiz Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
|
E mail:
|
seyedalisonbolestan@gmail.com
|
Phone:
|
|
Mobile:
|
09133148745
|
|
|
Purpose:
|
To evaluate the short-term effects of a single intravitreal injection of 1.25 mg
Bevacizumab combined with 300 lg/0.1 ml Diclofenac (IVB/D) versus 1.25 mg
intravitreal Bevacizumab (IVB) alone in treatment of naive diabetic macular edema
(DME).
|
Methods:
|
In this prospective, randomized clinical trial, 80 eyes were included in the
final analysis; 42 and 38 of which in the IVB and IVB/D groups, respectively. The
primary outcome measure was a change in best-corrected visual acuity (BCVA) in
logMAR at week 4. The secondary outcomes included changes in central macular
thickness (CMT), macular volume and potential injection-related complications.
|
Results:
|
Significant improvement of BCVA was demonstrated in both study arms
(mean reductions in LogMAR: -0.088±0.278, -0.228±0.330 for IVB, and IVB/D,
respectively). The difference in BCVA changes was in favor of IVB/D; however, not to a
statistically significant level (p=0.160). Significant reduction of CMT was documented in
both study arms (mean reductions: 82.43±160.09 and 153.26±163.85 for IVB, and
IVB+IVD, respectively). Comparison of CMT changes between groups showed that
IVB/D reduced CMT more than that of IVB (p=0.04). Effects on macular volume
corresponded to those of CMT. No injection-related complications or significant
alterations in intraocular pressure were observed in any of the study arms.
|
Conclusion:
|
In treatment-naive DME, superiority of IVB/D combination therapy overIVB monotherapy may exist; especially as regards anatomical features. In our
therapeutic arsenal for DME, IVD can be added as an adjunct to Bevacizumab.
|
Attachment:
|
|
|
|